Invacare 2014 Annual Report Download - page 116

Download and view the complete annual report

Please find page 116 of the 2014 Invacare annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 136

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136

INVACARE CORPORATION AND SUBSIDIAIRIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-(Continued)
FS-46
Net sales by product, are as follows (in thousands):
2014 2013 2012
North America/HME
Lifestyle Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 239,625 $ 267,934 $ 288,144
Mobility and Seating . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115,776 134,995 240,911
Respiratory Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149,063 178,065 134,663
Other(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,403 8,246 12,064
$ 507,867 $ 589,240 $ 675,782
Institutional Products Group
Continuing Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 102,796 $ 112,290 $ 126,508
Europe
Lifestyle Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 322,370 $ 303,225 $ 285,707
Mobility and Seating . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228,163 216,152 204,613
Respiratory Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40,661 40,885 42,700
Other(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19,361 22,881 13,523
$ 610,555 $ 583,143 $ 546,543
Asia/Pacific
Mobility and Seating . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 28,174 $ 26,737 $ 31,410
Lifestyle Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,772 12,023 15,448
Continuing Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,956 2,785 2,795
Respiratory Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,286 1,290 700
Other(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,757 6,997 16,632
$ 48,945 $ 49,832 $ 66,985
Total Consolidated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,270,163 $ 1,334,505 $ 1,415,818
________________________
(1) Includes various services, including repair services, equipment rentals and external contracting.
No single customer accounted for more than 2.9% of the Company’s sales.
Contingencies
General
In the ordinary course of its business, the Company is a defendant in a number of lawsuits, primarily product liability actions
in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits
that the Company faces in the United States have been referred to the Company's captive insurance company and/or excess insurance
carriers while all non-U.S. lawsuits have been referred to the Company's commercial insurance carriers. All such lawsuits are
generally contested vigorously. The coverage territory of the Company's insurance is worldwide with the exception of those
countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has
suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates.
Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes
available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating
certain exposures.
As a medical device manufacturer, the Company is subject to extensive government regulation, including numerous laws
directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing,
invoicing, documenting and other practices of health care suppliers and manufacturers are all subject to government scrutiny. Most
of the Company's facilities are subject to periodic inspection by the FDA or similar medical device regulatory agencies in other
jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, which could
have a material adverse effect on the Company's business.